Nov 11, 2025 08:52AM Altimmune publishes MASH trial results in The Lancet

Nov 7, 2025 08:06AM Altimmune presents AI analysis showing liver fibrosis reduction with pemvidutide

Nov 6, 2025 07:02AM Altimmune, Inc. (ALT) Tops Q3 EPS by 6c

Oct 20, 2025 06:56AM H.C. Wainwright Reiterates Buy Rating on Altimmune (ALT)

Sep 19, 2025 06:50AM H.C. Wainwright Reiterates Buy Rating on Altimmune (ALT)

Aug 12, 2025 07:00AM Altimmune, Inc. (ALT) Tops Q2 EPS by 4c

Aug 11, 2025 07:30AM Altimmune names Jerry Durso as board chairman

Jul 10, 2025 04:14AM Altimmune (ALT) PT Lowered to $15 at Citizens JMP

Jul 10, 2025 02:22AM Goldman Sachs Resumes Altimmune (ALT) at Sell

Jul 9, 2025 07:30AM Altimmune begins phase 2 trial for pemvidutide in liver disease

Jun 27, 2025 10:02AM UBS Reiterates Buy Rating on Altimmune (ALT)

Jun 27, 2025 06:52AM H.C. Wainwright Reiterates Buy Rating on Altimmune (ALT)

Jun 26, 2025 07:02AM Altimmune (ALT) Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide

Jun 5, 2025 04:24AM Citizens JMP Reiterates Market Outperform Rating on Altimmune (ALT)

Jun 2, 2025 07:07AM Stifel Reiterates Buy Rating on Altimmune (ALT)

May 19, 2025 07:31AM Altimmune (ALT) Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder

May 14, 2025 07:37AM Piper Sandler on Altimmune (ALT): 'An opportune Time to Buy Ahead of IMPACT Data'

May 13, 2025 07:02AM Altimmune, Inc. (ALT) Tops Q1 EPS by 12c

May 13, 2025 07:01AM Altimmune (ALT) Secures Up to $100M in Credit Facility from Hercules Capital

May 12, 2025 07:53AM Stifel Reiterates Buy Rating on Altimmune (ALT)

Apr 23, 2025 04:15AM Citizens JMP Reiterates Market Outperform Rating on Altimmune (ALT)

Apr 4, 2025 06:42AM H.C. Wainwright Reiterates Buy Rating on Altimmune (ALT)

Apr 2, 2025 04:38AM Citizens JMP Reiterates Market Outperform Rating on Altimmune (ALT)

Mar 16, 2025 04:00AM Bernstein forecasts US cable BB net adds in 2025

Mar 14, 2025 09:05AM Stifel Reiterates Buy Rating on Altimmune (ALT)

Mar 14, 2025 04:06AM Citizens JMP Reiterates Market Outperform Rating on Altimmune (ALT)

Mar 4, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on Altimmune (ALT)

Feb 27, 2025 04:59PM Altimmune (ALT) Files $400M Mixed Shelf

Feb 27, 2025 07:02AM Altimmune, Inc. (ALT) Tops Q4 EPS by 1c

Feb 6, 2025 06:42AM H.C. Wainwright Reiterates Buy Rating on Altimmune (ALT)

Jan 7, 2025 04:06PM Stifel Starts Altimmune (ALT) at Buy

Jan 3, 2025 08:23AM Piper Sandler Explores Direct and Indirect Catalysts for Selected Biotechnology Companies

Dec 19, 2024 07:30AM Altimmune (ALT) Added to Nasdaq Biotechnology Index

Nov 15, 2024 11:01AM Altimmune (ALT) Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease

Nov 12, 2024 07:02AM Altimmune, Inc. (ALT) Tops Q3 EPS by 4c

Nov 12, 2024 03:20AM UBS Starts Altimmune (ALT) at Buy

Nov 11, 2024 07:30AM Altimmune (ALT) Appoints Greg Weaver as CFO

Nov 7, 2024 07:30AM Altimmune (ALT) Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide

Sep 30, 2024 07:32AM Altimmune (ALT) Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis

Sep 10, 2024 07:46AM Altimmune (ALT) Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes

Sep 7, 2024 08:00PM Here's the list of biotech stocks that have key data catalysts in 2025

Sep 3, 2024 07:32AM Altimmune (ALT) Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes

Aug 8, 2024 07:01AM Altimmune, Inc. (ALT) Reports In-Line Q2 EPS

Jul 25, 2024 07:30AM Altimmune (ALT) Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease

Jun 27, 2024 10:28AM Altimmune (ALT) Climbs Following Mention in NY Post Article on Weight Loss

Jun 26, 2024 07:31AM Altimmune (ALT) Announces Passing of CFO Richard Eisenstadt

Jun 24, 2024 07:21AM Altimmune (ALT) Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at ADA